Episode Synopsis "Advancing Multidisciplinary Care in TGCT: Integrating Systemic Therapies and Surgical Approaches "

Host: William D. Tap, MD Host: John Healey, MD In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT. Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.​

Listen "Advancing Multidisciplinary Care in TGCT: Integrating Systemic Therapies and Surgical Approaches "

More episodes of the podcast Surgery

• Advancing Multidisciplinary Care in TGCT: Integrating Systemic Therapies and Surgical Approaches